Brief: SynAct Pharma Q4 Sales SEK 0
18/02/2026 06:30
Feb 18 (Reuters) - SynAct Pharma Q4 net income SEK -22.929 million. Q4 adjusted EPS SEK -0.43 Q4 operating expenses SEK 22.72 million Q4 cash flow from operating activities SEK -23.965 million
Recent news on SynAct Pharma AB
See all newsBrief: SynAct: Shareholding Board, Management Sign Lock-Up Agreements
Sweden's SynAct Pharma posts wider Q1 net loss as expenses rise
Brief: SynAct Pharma Q1 Sales SEK 0
Brief: SynAct Pharma Carries Out Directed Issue Of New Shares
Brief: Synact Pharma Appoints Ann Kristin Led As CFO Effective March 2026